Sirtex yet to peak: Wong
09 January, 2013 by Tim DeanSirtex Medical (ASX:SRX) CEO Gilman Wong is confident the company will continue to grow at a similar rate to the last five years, with it announcing its 34th consecutive quarter of growth.
Invion repurposes blood pressure drug to target asthma
08 January, 2013 by Tim DeanNadolol is known for its role in treating blood pressure, but now Invion is conducting a phase II trial to assess its effects on asthma and chronic bronchitis.
Sirtex shines as biotech gears up for big year
08 January, 2013 by AusBiotechAs the year commences, Sirtex Medical is being hailed a stand-out performer for 2012 and some analysts are tipping the biotech sector to be a “hot space” in 2013.
Bioniche wraps up with Endo, forges path for Urocidin
08 January, 2013 by Tim DeanAfter reclaiming the rights to its bladder cancer treatment, Urocidin, Bioniche (ASX:BNC) is now considering seeking approval in the Canadian market.
Alchemia pulls plug on Audeo Oncology demerger
21 December, 2012 by Tim DeanLack of investor interest has caused Alchemia to abandon plans to spin off its cancer business into a separate company, Audeo Oncology.
Bionomics’ BNC210 anti-anxiety drug enters phase I
21 December, 2012 by Tim DeanIronwood Pharmaceuticals has commenced a phase I trial of Bionomics’ (ASX:BNO) anti-anxiety drug, BNC210.
AusBiotech wraps up a year in biotechnology
20 December, 2012 by AusBiotechThis year Australia’s biotechnology industry can celebrate Christmas knowing that despite the challenges in the sector, companies in Australia can be proud of the year’s achievements.
Clinuvel success in Scenesse trial
19 December, 2012 by Tim DeanClinuvel (ASX:CUV) has shown in a phase IIa trial that its Scenesse implant in combination with UV therapy can aid in the treatment if skin pigmentation condition vitiligo.
Biotech bites: Sirtex to be listed on S&P/ASX 200
18 December, 2012 by Tim DeanSirtex Medical (ASX:SRX) will be added to the S&P/ASX 200 after Integra Mining Limited (ASX:IGR) was dropped from the list.
Annual global biopharmaceutical manufacturing survey is on again
18 December, 2012 by AusBiotechBiopharmaceutical manufacturers and contract manufacturing organisations (CMOs) are invited to participate in the bio-industry's most in-depth, global study: the 10th Annual Biopharmaceutical Manufacturing Report and Survey.
Invion to submit IND for lupus treatment in 2013
17 December, 2012 by Tim DeanFollowing a pre-IND meeting with the FDA that set the roadmap for clinical trials for its lupus treatment, Invion (ASX:IVX) will file an IND early next year.
Bionomics progressing with Alzheimer's drug
14 December, 2012 by Dylan Bushell-EmblingBionomics (ASX:BNO) has chosen an Alzheimer's treatment candidate from its alpha-7 programme, and is preparing for both clinical trials and a potential industry partnership.
ABCA gathers for Council’s inaugural meeting
13 December, 2012 by AusBiotechThe first meeting of the Agricultural Biotechnology Council of Australia (ABCA) took place in Canberra last week, signalling a new and significant era for Australian agriculture.
Alchemia in final stages of demerger
13 December, 2012 by Tim DeanAlchemia (ASX:ACL) has entered a trading halt as it is on the cusp of completing its demerger and spin-off of Audeo Oncology, which prepares for its IPO.
AusBiotech comments on FSANZ cost recovery plans for health claims applications
11 December, 2012 by AusBiotechAusBiotech has written to Food Standards Australia New Zealand (FSANZ) in response to its consultation on proposed cost recovery arrangements for applications related to health claims, opposing the move.
